Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 287-722-1 | CAS number: 85567-10-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vitro
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 05.10-2017.-26-01-2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 018
- Report date:
- 2018
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: OECD guideline 442E (In vitro Skin Sensitisation: human Cell Line Activation Test (h-CLAT))
- Version / remarks:
- 29 July 2016
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- activation of dendritic cells
- Justification for non-LLNA method:
- In accordance with Annex VII of REACH regulation
Test material
- Reference substance name:
- 4,5-dihydro-5-oxo-4-[[4-[[2-(sulphooxy)ethyl]sulphonyl]phenyl]azo]-1-(4-sulphophenyl)-1H-pyrazole-3-carboxylic acid, sodium salt
- EC Number:
- 287-722-1
- EC Name:
- 4,5-dihydro-5-oxo-4-[[4-[[2-(sulphooxy)ethyl]sulphonyl]phenyl]azo]-1-(4-sulphophenyl)-1H-pyrazole-3-carboxylic acid, sodium salt
- Cas Number:
- 85567-10-8
- Molecular formula:
- C18H13N4Na3O12S3
- IUPAC Name:
- trisodium 5-oxo-4-(2-{4-[2-(sulfonatooxy)ethanesulfonyl]phenyl}diazen-1-yl)-1-(4-sulfonatophenyl)-4,5-dihydro-1H-pyrazole-3-carboxylate
- Test material form:
- solid
Constituent 1
- Specific details on test material used for the study:
- STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: room temperature, protected from light
- Stability under test conditions: yes
- Solubility and stability of the test substance in the solvent/vehicle: stable
In vitro test system
- Details on the study design:
- TEST SYSTEM
- Cell line: THP-1 cells; human monocytic leukemia cell line (ATCC TIB-202)
TEST-SUBSTANCE PREPARATION
- Concentration dose finding assay 1: 1000, 500, 250, 125, 62.5, 31.25, 15.63 and 7.81 µg/mL
- Concentration dose finding assay 2: 5000, 2500, 1250, 625, 312.5, 156.25, 78.13 and 39.06 µg/mL
- Concentrations: experiment 1 and 2: 5000, 4166.67, 3472.22, 2893.52, 2411.27, 2009.39, 1674.49, 1395.41 µg/mL.
- Vehicle: 0.9% NaCl
CONTROLS
- Solvent control: 0.2% DMSO (v/v) in cell culture medium
- Positive control: 1-chloro-2-4-dinitrobenzene (DNCB) at a final conc. of 4.0 μg/mL
MEDIUM
- Culture medium: RPMI 1640: with 2 mM L-glutamine, 25mM HEPES + 10% FBS + 100 U/ml Penicillin/100 µg/mL Streptomycin + 0.05 mM 2-mercaptoethanol
- FACS Buffer: Phosphate Buffered Saline (DPBS) + 0.1% BSA
- Blocking buffer: FcR blocking buffer (FACS buffer containing 0.01% (w/v) Globulin Cohn Fraction)
- Reagent for cytotoxicity test: Propidium iodide (Sigma)
EXPERIMENTAL PROCEDURE
- Replicates: 1
- Experiments: 2
- Exposure period: 24 ± 0.5 hours
- Preparation of cells: THP-1 cells were thawed and cultured in complete RPMI 1640 medium supplemented with 10% fetal bovine serum, penicillin, streptomycin and 2 -mercaptethanol
ANALYSIS
- FACS: cell staining and flow cytometric analysis 24 ± 0.5 hours after exposure
DATA EVALUATION
- CV75 calculation: Relative survival rate is calculated by linear extrapolation. This value is the substance concentration at which cell viability is 75% compared to the vehicle control.
- Relative cell viability: % relative cell viability = (number of living cells / total number of aquired cells)* 100
- Relative fluorescence intensity: RFI (%) = ( MFI of chemical-treated cells - MFI of chemical-treated isotype control cells) / (MFI of vehicle control cells - MFI of vehicle isotype control cells) * 100
EVALUATION RESULTS
- Positive result: A test is considered to be positive when the dendritic cells are activated meaning that CD86 expression is increased ≥150% and/or CD54 expression increased ≥ 200% in relation to vehicle control in at least 2 independent experiments (cell vialbility ≥ 50%)
- Negative result: A negative test result of a test item was only accepted if the cell viability at a concentration of 1.2 x CV75 is <90%.
ACCEPTANCE CRITERIA
The test meets acceptance criteria if:
- the cell viability of the solvent controls is >90%,
- the cell viability of at least four tested doses of the test item in each run is >50%,
- the RFI values of the positive control (DNCB) is ≥150% for CD86 and ≥200% for CD54 at a cell viability of >50%,
- the RFI values of the solvent control is not ≥150% for CD86 and not ≥200% for CD54,
- the MFI ratio of CD86 and CD54 to isotype IgG1 control for the medium and DMSO control, is >105%.
Results and discussion
- Positive control results:
- The positive control (DNCB) led to an upregulation of the expression of CD54 and CD86 in both experiments.
The threshold of 150% for CD86 (415% experiment 1; 376% experiment 2) and 200% for CD54 (312% experiment 1; 476% experiment 2) were clearly exceeded.
In vitro / in chemico
Resultsopen allclose all
- Key result
- Run / experiment:
- other: experiment 1
- Parameter:
- other: CD86 expression (%)
- Value:
- 150
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Run / experiment:
- other: experiment 2
- Parameter:
- other: CD86 expression (%)
- Value:
- 150
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- no indication of skin sensitisation
- Run / experiment:
- other: experiment 1
- Parameter:
- other: CD54 expression (%)
- Value:
- 200
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Run / experiment:
- other: experiment 2
- Parameter:
- other: CD54 expression (%)
- Value:
- 200
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- no indication of skin sensitisation
- Other effects / acceptance of results:
- The controls confirmed the validity of the study.
The viability of the solvent control was > 90% (96.3-98.3% experiment 1; 97.1-97.69% experiment 2).
The number of tested test item concentrations with cell viability > 50% was ≥ 4 (8 in experiment 1 and 8 in experiment 2).
The RFI for CD86 and CD54 of cells treated with the solvent DMSO was < 150% (131% experiment 1; 117% experiment 2) and ≤ 200% (113% experiment 1; 88% experiment 2).
The MFI ratio of the medium control and isotype IgG1control was ≥ 105% for CD86 (149% experiment 1; 206% experiment 2) and CD54 (129% experiment 1; 171% experiment 2).
The MFI ratio of the solvent control (DMSO) and isotype IgG1 control was ≥ 105% for CD86 (173% experiment 1; 2256% experiment 2) and CD54 (137% experiment 1; 163% experiment 2).
Any other information on results incl. tables
CD54 and CD86 Expression Experiment 1
Sample | Conc (mg/ml) | Cell Viability (%) CD86 | Cell Viability (%) CD54 | RFI (%) CD 86 | RFI (%) CD54 |
Medium control | 98.3 | 97.7 | 100 | 100 | |
Solvent Control | 0.20% | 96.4 | 96.3 | 131 | 113 |
DNCB | 4.0 | 82.0 | 80.4 | 404 | 476 |
Test item | 5000 | 92.3 | 93.1 | -7 | 142 |
4166.67 | 93.4 | 92.7 | 2 | 163 | |
3472.22 | 93.0 | 93.5 | 13 | 168 | |
2893.52 | 93.5 | 92.1 | 12 | 175 | |
2411.27 | 93.3 | 93.9 | 18 | 119 | |
2009.39 | 94.5 | 93.3 | 21 | 99 | |
1674.49 | 94.4 | 95.0 | 22 | 88 | |
1395.41 | 93.8 | 93.5 | 32 | 92 |
CD54 and CD86 Expression Experiment 2
Sample | Conc (mg/ml) | Cell Viability (%) CD86 | Cell Viability (%) CD54 | RFI (%) CD 86 | RFI (%) CD54 |
Medium control | 97.2 | 97.4 | 100 | 100 | |
Solvent Control | 0.20% | 97.6 | 97.4 | 117 | 88 |
DNCB | 4.0 | 80.2 | 81.1 | 317 | 410 |
test item | 5000 | 92.1 | 90.7 | -4 | 55 |
4166.67 | 93.2 | 92.5 | 3 | 96 | |
3472.22 | 93.1 | 92.6 | 7 | 105 | |
2893.52 | 93.1 | 93.3 | 18 | 95 | |
2411.27 | 94.6 | 95.0 | 11 | 69 | |
2009.39 | 95.0 | 94.7 | -2 | 24 | |
1674.49 | 95.2 | 94.6 | 28 | 65 | |
1395.41 | 95.4 | 95.3 | 28 | 60 |
Applicant's summary and conclusion
- Interpretation of results:
- other: The study alone cannot be used for the classification purpose but in a WoE approach
- Conclusions:
- The test item did not upregulate the cell surface marker in at least two independant runs.
Therefore, the test item might be considered as non-sensitiser. - Executive summary:
In the current study the skin sensitisation potential of the test item was assessed according to the new OECD 442E TG and in compliance to GLP.
The in vitro human cell line activation test (h-CLAT) enables detection of the sensitising potential of a test item by addressing the third molecular key event of the adverse outcome pathway (AOP), namely dendritic cell activation, by quantifying the expression of the cell surface markers CD54 and CD86 in the human monocytic cell line THP-1. The expression of the cell surface markers compared to the respective solvent controls is used to support discrimination between skin sensitiser and non-sensitisers.
Prior to the main study the cell batch was checked for its reactivity towards known positive and negative controls and was found to be acceptable for further testing.
The test item was dissolved in 0.9% NaCl. After exposure cells were stained with propidium iodide and cell viability was measured by FACS analysis. No CV75 was derived in the dose finding assay.
The main experiment was performed covering the following concentration steps:
5000, 4166.67, 3472.22, 2893.52, 2411.27, 2009.39, 1674.49 and 1395.41 µg/mL
Cells were incubated with the test item for 24 h at 37°C. After exposure cells were stained and cell surface markers CD54 and CD86 were measured by FACS analysis. Cell viability was assessed in parallel using propidium iodide staining.
No cytotoxicity effects were observed for the cells treated with the test item. Relative cell viability at the highest test item concentration was reduced to 92.3% (CD86), 93.1% (CD54) and 92.1% (isotype IgG1 control) in the first experiment. and to 92.1% (CD86), 90.7% (CD54) and 89.8% (isotype IgG1 control).
The expression of the cell surface marker CD86 was not upregulated above the threshold of 150% in any of the experiments. The expression of cell surface marker CD54 was not upregulated above the threshold of 200% in any of the experiments. Therefore, the test item might be considered as non-sensitiser.
The positive control (DNCB) led to an upregulation of the expression of CD54 and CD86 in both experiments. The threshold of 150% for CD86 (404% experiment 1; 317% experiment 2) and 200% for CD54 (476% experiment 1; 410% experiment 2) were clearly exceeded.
In this study under the given conditions the test item did not upregulate the expression of the cell surface marker in at least two independent experiment runs. Therefore, the test item might be considered as non-sensitiser.
The data generated with this method may be not sufficient to conclude on the skin sensitisation potential of chemicals and should be considered in a weight of evidence approach in which minimally 2 key events of the adverse outcome pathway (AOP) are tested.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.